Quantum BioPharma Approved to Dual List on Upstream Global Trading App
Shares of Quantum BioPharma will be available to trade on the Upstream app on January 14th under the ticker symbol 'QNTM'.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) announced it was approved to dual list its shares on the Upstream global securities trading app. Shares of Quantum BioPharma stock will be available to trade on the Upstream app on January 14th, 2025, at 10 am EST under the ticker symbol ‘QNTM.’
The dual Upstream listing is designed to provide Quantum BioPharma with the opportunity to unlock additional liquidity by accessing a new global investor base outside the United States.
Quantum BioPharma CEO Zeeshan Saeed commented on the announcement, stating:
“Building shareholder value is an ongoing goal of ours. We believe a dual listing on Upstream’s next-generation market supports this goal as we continue to develop our potential game-changing drug candidates for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders that impact people from all over the world.”
What is Upstream?
Upstream is a global securities trading app on the MERJ Exchange market powered by Horizon’s proprietary, transparency-first matching engine. The smart contract-powered platform provides investors with real-time trading and settlement, as well as a transparent orderbook that doesn’t allow market manipulations.
Upstream allows investors outside the United States to trade securities using only an app. It also offers account holders multiple convenient options for funding their accounts, including credit card, debit card, PayPal, USD, or USDC.
Another unique feature of Upstream is that its trading market is open 20 hours a day, seven days a week, from 1 am to 9 pm EST.
How to Get Started on Upstream
Investors outside the United States can download the Upstream app via the Apple App Store or Google Play. From there, they can create an account by tapping the signup button, completing a simple KYC identity verification by tapping the profile icon on the home screen and then KYC.
Existing non-US Quantum BioPharma shareholders can transfer their QNTM shares to Upstream by completing the following steps:
- Open the Upstream app.
- Tap “Investor.”
- Followed by “Manage Securities,” then “Deposit Securities.”
- Enter the ticker symbol “QNTM” and the number of shares to deposit, followed by tapping “Submit.”
- Next, enter the name of the brokerage firm and the account number, then tap “Submit.”
- Finally, tap “Add E-Signature,” then sign your name on the screen with your finger. Then tap “Done,” followed by “Sign.”
After completing the Upstream deposit request, QNTM shareholders will receive an email with an executed deposit form. They can then submit the form to their current brokerage firm to initiate the withdrawal to the transfer agent.
On the listing day, QNTM shareholders will receive a push notification on the Upstream app to let them know that the shares have been deposited and are available for trading.
Additional information on the Quantum BioPharma Upstream listing, deposit, and trading instructions can be accessed on the company’s website by clicking here.
Read Next: Why This Small Biotech Stock Could Be Primed for a Breakout
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
